These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15492351)

  • 1. Ezetimibe and statin-associated myopathy.
    Phillips PS
    Ann Intern Med; 2004 Oct; 141(8):649. PubMed ID: 15492351
    [No Abstract]   [Full Text] [Related]  

  • 2. Ezetimibe and statin-associated myopathy.
    Fux R; Mörike K; Gundel UF; Hartmann R; Gleiter CH
    Ann Intern Med; 2004 Apr; 140(8):671-2. PubMed ID: 15096354
    [No Abstract]   [Full Text] [Related]  

  • 3. Worsening myopathy associated with ezetimibe in a patient with McArdle disease.
    Perez-Calvo J; Civeira-Murillo F; Cabello A
    QJM; 2005 Jun; 98(6):461-2. PubMed ID: 15897216
    [No Abstract]   [Full Text] [Related]  

  • 4. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Simard C; Poirier P
    Can J Cardiol; 2006 Feb; 22(2):141-4. PubMed ID: 16485049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin myopathy as a metabolic muscle disease.
    Phillips PS; Haas RH
    Expert Rev Cardiovasc Ther; 2008 Aug; 6(7):971-8. PubMed ID: 18666847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-lowering therapy--benefits and risks.
    Shechter M
    Isr Med Assoc J; 2007 Feb; 9(2):133; author reply 133-4. PubMed ID: 17348492
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipid-lowering therapy--benefits and risks.
    Abinader EG
    Isr Med Assoc J; 2007 Feb; 9(2):132-3; author reply 133-4. PubMed ID: 17354321
    [No Abstract]   [Full Text] [Related]  

  • 8. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials.
    Kashani A; Sallam T; Bheemreddy S; Mann DL; Wang Y; Foody JM
    Am J Cardiol; 2008 Jun; 101(11):1606-13. PubMed ID: 18489938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive lipid-lowering therapy: obvious benefits, possible risks.
    Zimlichman E; Szyper-Kravitz M; Katz U; Shoenfeld Y
    Isr Med Assoc J; 2006 Dec; 8(12):890-1. PubMed ID: 17214117
    [No Abstract]   [Full Text] [Related]  

  • 10. [Reversible myopathy due to ezetimibe].
    Canora Lebrato J; Frutos Pérez B; Gutiérrez Gutiérrez G; Zapatero Gaviria A
    Med Clin (Barc); 2007 Feb; 128(6):237-8. PubMed ID: 17335730
    [No Abstract]   [Full Text] [Related]  

  • 11. [Statin intolerance].
    Graversen CB; Larsen ML; Schmidt EB
    Ugeskr Laeger; 2015 Aug; 177(36):. PubMed ID: 26324293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myopathy induced by statin-ezetimibe combination: Evaluation of potential risk factors.
    Brahmachari B; Chatterjee S
    Indian J Pharmacol; 2015; 47(5):563-4. PubMed ID: 26600650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Narrative review: statin-related myopathy.
    Joy TR; Hegele RA
    Ann Intern Med; 2009 Jun; 150(12):858-68. PubMed ID: 19528564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators.
    Whayne TF
    Angiology; 2011 Jul; 62(5):415-21. PubMed ID: 21421631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
    Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
    Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin-related myopathy.
    Dobkin BH
    Arch Intern Med; 2006 Jun; 166(11):1232; author reply 1233. PubMed ID: 16772253
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.
    Moriarty PM; Thompson PD; Cannon CP; Guyton JR; Bergeron J; Zieve FJ; Bruckert E; Jacobson TA; Kopecky SL; Baccara-Dinet MT; Du Y; Pordy R; Gipe DA;
    J Clin Lipidol; 2015; 9(6):758-769. PubMed ID: 26687696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observations from a statin myopathy clinic.
    Phillips PS; Haas RH
    Arch Intern Med; 2006 Jun; 166(11):1232-3; author reply 1233. PubMed ID: 16772252
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients.
    Suzuki H; Watanabe Y; Kumagai H; Shuto H
    Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):306-15. PubMed ID: 24280596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
    Okada K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S; Kimura K
    Atherosclerosis; 2012 Oct; 224(2):454-6. PubMed ID: 22892323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.